Pomerantz Law Firm Probes ADC Therapeutics Over Investor Claims of Possible Fraudulent Practices
In a developing story regarding ADC Therapeutics SA, the Pomerantz Law Firm is initiating an investigation into claims put forth by investors of the biotechnology company, which trades on the NYSE under the ticker symbol ADCT. The investigation closely examines whether ADC and some of its executives have participated in fraudulent activities related to securities, casting a shadow over the company's business practices.
This inquiry arises from significant concerns following ADC's recent announcement on June 3, 2026. The firm reported topline data from its Phase 3 LOTIS-5 trial, which assessed the efficacy of ZYNLONTA® (loncastuximab tesirine-lpyl) used in synergy with rituximab for patients diagnosed with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). While the results indicated that this treatment could extend progression-free survival by an estimated 1.4 months, the associated increase in patient mortality raises serious alarms. During the trial, 27 patient deaths were attributed to the Zynlonta treatment, contrasted with only nine deaths recorded among those receiving standard immunotherapy.
The revelation of such adverse outcomes prompted a swift and severe reaction from the market. Following the release of these concerning trial results, ADC's stock plummeted dramatically. In just two trading days, the share price dropped by $2.05, reflecting a staggering 66.56% loss, ultimately closing at $1.03 per share by June 5, 2026. This decline has intensified scrutiny from investors who may allege that the company failed to provide adequate warning of risks associated with its treatments, thereby potentially deceiving stakeholders.
Investors or individuals who suspect they may have experienced losses due to ADC's business practices are encouraged to reach out to Pomerantz Law Firm. Danielle Peyton, a representative from the firm, can be contacted directly via email at [email protected] or by phone at 646-581-9980, extension 7980. This outreach is crucial for those looking to understand their legal standing or to get involved in potential class-action mechanisms that may arise from this situation.
Pomerantz LLP, renowned for its expertise in securities litigation, has a storied history dating back more than 85 years. The firm, founded by the late Abraham L. Pomerantz—often referred to as the "dean of the class action bar"—has distinguished itself in the arenas of corporate, securities, and antitrust litigation. They have diligently advocated for victims of securities fraud, earning significant recoveries for those affected by corporate misconduct. As this situation evolves, Pomerantz is positioned to leverage its substantial expertise to assist investors navigating these tumultuous waters. Investors might find solace in the fact that the firm's previous successes could hint at favorable outcomes moving forward, although it’s essential to note that prior results do not guarantee similar outcomes.
For ADC Therapeutics, the spotlight is on as the implications of its recent clinical trial results bond with the ongoing investigation, posing questions about accountability, corporate governance, and the welfare of patients relying on effective cancer treatment.
As shares of ADC Therapeutics remain in flux, the focus shifts to the firm’s strategic response in addressing investor concerns and restoring confidence in its operational integrity. The unfolding narrative surrounding ADC serves as a crucial reminder of the complexities inherent in the biotech sector, where the delicate balance between innovation and accountability can often feel precarious. As this investigation continues, all eyes will remain on ADC Therapeutics and Pomerantz Law Firm, both of which will define the next chapter of this potential legal saga.
This inquiry arises from significant concerns following ADC's recent announcement on June 3, 2026. The firm reported topline data from its Phase 3 LOTIS-5 trial, which assessed the efficacy of ZYNLONTA® (loncastuximab tesirine-lpyl) used in synergy with rituximab for patients diagnosed with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). While the results indicated that this treatment could extend progression-free survival by an estimated 1.4 months, the associated increase in patient mortality raises serious alarms. During the trial, 27 patient deaths were attributed to the Zynlonta treatment, contrasted with only nine deaths recorded among those receiving standard immunotherapy.
The revelation of such adverse outcomes prompted a swift and severe reaction from the market. Following the release of these concerning trial results, ADC's stock plummeted dramatically. In just two trading days, the share price dropped by $2.05, reflecting a staggering 66.56% loss, ultimately closing at $1.03 per share by June 5, 2026. This decline has intensified scrutiny from investors who may allege that the company failed to provide adequate warning of risks associated with its treatments, thereby potentially deceiving stakeholders.
Investors or individuals who suspect they may have experienced losses due to ADC's business practices are encouraged to reach out to Pomerantz Law Firm. Danielle Peyton, a representative from the firm, can be contacted directly via email at [email protected] or by phone at 646-581-9980, extension 7980. This outreach is crucial for those looking to understand their legal standing or to get involved in potential class-action mechanisms that may arise from this situation.
Pomerantz LLP, renowned for its expertise in securities litigation, has a storied history dating back more than 85 years. The firm, founded by the late Abraham L. Pomerantz—often referred to as the "dean of the class action bar"—has distinguished itself in the arenas of corporate, securities, and antitrust litigation. They have diligently advocated for victims of securities fraud, earning significant recoveries for those affected by corporate misconduct. As this situation evolves, Pomerantz is positioned to leverage its substantial expertise to assist investors navigating these tumultuous waters. Investors might find solace in the fact that the firm's previous successes could hint at favorable outcomes moving forward, although it’s essential to note that prior results do not guarantee similar outcomes.
For ADC Therapeutics, the spotlight is on as the implications of its recent clinical trial results bond with the ongoing investigation, posing questions about accountability, corporate governance, and the welfare of patients relying on effective cancer treatment.
As shares of ADC Therapeutics remain in flux, the focus shifts to the firm’s strategic response in addressing investor concerns and restoring confidence in its operational integrity. The unfolding narrative surrounding ADC serves as a crucial reminder of the complexities inherent in the biotech sector, where the delicate balance between innovation and accountability can often feel precarious. As this investigation continues, all eyes will remain on ADC Therapeutics and Pomerantz Law Firm, both of which will define the next chapter of this potential legal saga.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.